DOCSLIB.ORG

User's Manual: Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
User's Manual: Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) Laboratory Assessment of Antibiotic Resistance Testing Capacity User’s Guide and Questionnaire VERSION 2.0 AUGUST 2020 Division of Healthcare Quality Promotion CS320242-A LAARC User’s Guide and Questionnaire Version 2.0 August 2020 The Laboratory Assessment of Antibiotic Resistance Testing Capacity is a publication of the Division of Healthcare Quality Promotion in the National Center for Emerging and Zoonotic Infectious Diseases within the U.S. Centers for Disease Control and Prevention (CDC). U.S. Centers for Disease Control and Prevention Robert Redfield, MD, Director National Center for Emerging and Zoonotic Infectious Diseases Rima Khabbaz, MD, Director Division of Healthcare Quality Promotion Denise Cardo, MD, Director Photo Credit: Daniella Coker Cover page photo features (l-r) Dr. Hein Bui of CDC, Vietnam; Mr. Truong Nguyen, a healthcare informatics consultant in Vietnam; and Dr. Mai Van Tuan, a clinical microbiologist in Hue, Vietnam. They are examining a lidded and sealed non-infectious petri dish in an anteroom of a non-CDC laboratory in Vietnam. Suggested citation: Centers for Disease Control and Prevention. Laboratory Assessment of Antibiotic Resistance Testing Capacity. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2020. Available at: https://www.cdc.gov/drugresistance/intl-activities/laarc.html. Version 2 | August 2020 Page 1 of 90 LAARC User’s Guide and Questionnaire ACKNOWLEDGEMENTS Susan Bollinger (International Infection Control Program, Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA) led the overall development of the LAARC questionnaire and coordinated the piloting and revision of the tool in collaboration with internal and external stakeholders. She also provided expert subject matter input to the development of the Excel scoring tool. Sonya Arundar and Joyce Thomas (Division of Healthcare Quality Promotion, CDC) provided professional editing (plain language and usability) assistance. Antoine Pierson (Integrated Quality Laboratory Services, IQLS, Lyon, France) led the development of the Excel scoring tool and provided expert subject matter input on the LAARC content to optimize the use of the scoring tool. Additional support was provided by Abdoulaye Nikièma (IQLS). The following experts participated in technical consultations to guide the development and provided technical review of the tool: Rachel Smith, Ulzii Luvsansharav, Nora Chea, Michael Omondi, T.J. McKinney (Division of Healthcare Quality Promotion, CDC), Michele Parsons (Division of Global Health Protection, CDC). The following experts piloted the tool in resource-limited settings and provided technical expertise and feedback: Nino Macharashvili, Lan Nguyen, Hien Bui, Valan Siromany, Wangeci Gatei, Molly Freeman, Pawan Angra (Division of Global Health Protection, CDC). Lynee Galley, Emma Muir, Martin Evans, John TarBush, John Aldom, Abdul Chagla, Vlademir Cantarelli, Victor Silva, American Society for Microbiology (ASM); Mona ElShokry, Dana Itani, Walaa Khater, the World Health Organization (WHO); and Lindsey Shields, Rogers Kisame, Moctar Mouiche, (FHI360). Funding for the development of the Excel scoring tool was provided by the Division of Global Health Protection in the Center for Global Health through a Cooperative Agreement. DISCLAIMERS All rights reserved. Publication of the Centers for Disease Control and Prevention is available on the U.S. CDC website Lab Assessment of Antibiotic Resistance Testing Capacity (LAARC) (https://www.cdc.gov/drugresistance/intl-activities/laarc.html) or can be obtained from Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA, 30329, USA (email: [email protected]). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the Centers for Disease Control and Prevention in preference to others of a similar nature who are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The contents of the LAARC are solely the responsibility of the authors and do not necessarily represent the official views of the U.S. Centers for Disease Control and Prevention. All reasonable precautions have been taken to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and uses of the material lies with the reader. In no event shall the Centers for Disease Control and Prevention or IQLS be liable for damages arising from its use. Version 2 | August 2020 Page 2 of 90 LAARC User’s Guide and Questionnaire TABLE OF CONTENTS ACKNOWLEDGEMENTS ..............................................................................................................................................2 DISCLAIMERS ..............................................................................................................................................................2 TABLES AND FIGURES .................................................................................................................................................4 ACRONYMS .................................................................................................................................................................5 EXECUTIVE SUMMARY ................................................................................................................................................7 1. INTRODUCTION .................................................................................................................................................7 1.1. Rationale .................................................................................................................................................7 1.2. Purpose ...................................................................................................................................................7 1.3. Scope .......................................................................................................................................................8 2. ASSESSMENT PLANNING and PREPARATION ................................................................................................ 10 2.1. Assessment Team ................................................................................................................................ 10 2.2. Team Preparation ................................................................................................................................ 10 2.3. Laboratory Preparation ........................................................................................................................ 11 2.4. Assessment Process ............................................................................................................................. 11 2.4.1. Take GPS Location ...................................................................................................................... 11 2.4.2. Meet with staff ........................................................................................................................... 11 2.4.3. Tour the laboratory .................................................................................................................... 12 2.4.4. Review Documents and Fill the Questionnaire .......................................................................... 12 2.4.5. Professionalism .......................................................................................................................... 12 3. LAARC TOOL STRUCTURE ............................................................................................................................... 13 3.1. Files ...................................................................................................................................................... 13 3.2. Excel File Organization ......................................................................................................................... 13 3.2.1. Yellow: ....................................................................................................................................... 13 3.2.2. Blue: Questionnaire (15 tabs) .................................................................................................... 13 3.2.3. Questionnaire Organization and Structure ................................................................................ 14 3.2.4. Red: ........................................................................................................................................... 15 4. ENTERING DATA INTO THE EXCEL TOOL ........................................................................................................ 16 4.1. Generate a Unique Filename ............................................................................................................... 16 4.2. Select Language ................................................................................................................................... 16 4.3. Answer Questions ................................................................................................................................ 16 4.3.1. Drop-down boxes ....................................................................................................................... 16 4.3.2. Free-text cells and Comment cells ............................................................................................
Load more

Recommended publications
  • Characterization and Antibiotic Sensitivity Profile of Bacteria Isolated from Patients with Respiratory Tract Infections in Bangladesh
    Characterization and Antibiotic Sensitivity Profile of Bacteria Isolated from Patients with Respiratory Tract Infections in Bangladesh Shukla Promite1, Sajal K. Saha2, Sunjukta Ahsan1 and Marufa Zerin Akhter1 1Department of Microbiology, University of Dhaka, Dhaka, Bangladesh 2Department of General Practice, Monash University, Building 1, 270 Ferntree Gully Road, Notting Hill VIC 3168, Australia (Received: October 08, 2017; Accepted: December 15, 2017; Published (web): December 23, 2017) ABSTRACT: The study was aimed to characterize bacterial isolates from respiratory tract infections (RTI) and investigate their antibiotic sensitivity profile. Selective media and biochemical tests were used to characterize 40 bacterial isolates. Antibiotic sensitivity testing was conducted using Kirby-Bauer disc diffusion method. About 42.5% (17) RTI patients were infected by Klebsiella pneumoniae, 30% (12) by Escherichia coli and 27.5% (11) by Pseudomonas aeruginosa with no significant gender variation (p-value <0.578). Overall, 47% (out of 20) antibiotics were sensitive, whereas 48% were resistant. Surprisingly, 18% P. aeruginosa and 20% K. pneumoniae were carbapenem-resistant and 4 out of 7 cephalosporin antibiotics were highly resistant irrespective of pathogens. E. coli showed better sensitivity to nitrofurantoin (78%) and levofloxacin (89%), while K. pneumoniae was insensitive to cotrimoxazole (88%), gentamycin (77%) and piperacillin/tazobactam (66%). On the other hand, P. aeruginosa did not respond to P. aeruginosa to nalidixic acid (60%) and ciprofloxacin (60%). This study concludes that nitrofurantoin, levofloxacin, cotrimoxazole, gentamycin and piperacillin/tazobactam antibiotics could be better alternative in treating bacterial RTIs. Key words: Antibiotic sensitivity, bacterial pathogens, RTIs, Bangladesh. INTRODUCTION Antibiotic resistance (AR) is a global public The rise of AR in Bangladesh is probably due to 1 health concern.
    [Show full text]
  • Histopathology and Laboratory Features of Sexually Transmitted Diseases
    Histopath & Labs for STIs Endo, Energy and Repro 2017-2018 HISTOPATHOLOGY AND LABORATORY FEATURES OF SEXUALLY TRANSMITTED DISEASES Dominck Cavuoti, D.O. Phone: 469-419-3412 Email: [email protected] LEARNING OBJECTIVES: • Identify the etiologic agents causing pelvic inflammatory disease and the pathologic changes they produce. • Discuss the characteristic clinical and pathologic findings caused by herpes simplex virus (HSV) infections: a. fever blisters b. genital herpes simplex virus infection c. disseminated neonatal HSV • Describe the pathologic changes produced by Treponema pallidum. • Describe the clinical features and pathologic changes produced by Chlamydia trachomatisand Neisseria gonorrhoeae • Describe the clinical and laboratory features of vaginal infections including: Trichomonas, Candida, and bacterial vaginosis. • Describe the clinical and laboratory features of ectoparasite infections PURPOSE OF THE LECTURE: 1. To describe the various agents of sexually transmitted diseases and their disease manifestations 2. To describe the pathologic features associated with STDs 3. To introduce some of the laboratory aspects of STDs TERMS INTRODUCED IN LECTURE: Condyloma lata Disseminated gonococcal infection Gummatous syphilis Lymphogranuloma venereum Pelvic inflammatory disease Rapid Plasma Reagin (RPR) Salpingitis Syphilis/endarteritis obliterans Venereal Disease Research Laboratory (VDRL) Treponema pallidum particle agglutination (TPPA) Histopath & Labs for STIs Endo, Energy and Repro 2017-2018 MAJOR CONCEPTS EMPHASIZED IN LECTURE I. Syphilis (Will be covered by Dr. Norgard in later lecture). II. Gonorrhea A. Causative agent: Neisseria gonorrhoeae, a Gram negative diplococcus. Humans are the only natural reservoir. Infection is acquired via direct contact with the mucosa of an infected person. The incubation period averages 2-5 days with a range of 1-14 days.
    [Show full text]
  • Gst Gram Staining Learning Objectives the Student Will  Use Aseptic Techniques in the Safe Inoculation of Various Forms of Media
    GSt Gram Staining Learning Objectives The student will Use aseptic techniques in the safe inoculation of various forms of media. Follow oral and written instructions and manage time in the lab efficiently. Use the bright field light microscope to view microbes under oil immersion, make accurate observations and appropriate interpretations and store the microscope according to lab procedures. Properly prepare a bacterial smear for accurate staining and describe the chemical basis for simple staining and negative staining. Background/Theory Differential staining distinguishes organisms based on their interactions with multiple stains. In other words, two organisms may appear to be different colors. Differential staining techniques commonly used in clinical settings include Gram staining, acid-fast staining, endospore staining, flagella staining, and capsule staining. This link to the OpenStax Microbiology text provides more detail on these differential staining techniques. (OpenStax CNX, 2018) The Gram stain is a differential staining procedure that involves multiple steps. It was developed by Danish microbiologist Hans Christian Gram in 1884 as an effective method to distinguish between bacteria containing the two most common types of cell walls. (OpenStax CNX, 2018) One type consists of an inner plasma membrane and a thick outer layer of peptidoglycan. The other type consists of a double phospholipid Figure 1 Simplified structures of Gram negative cells (left) and Gram positive bilayer with a thin layer of cells (right) peptidoglycan between the two. The Gram Staining technique remains one of the most frequently used staining techniques. The steps of the Gram stain procedure are listed below and illustrated in Figure. (OpenStax CNX, 2018) 1.
    [Show full text]
  • MIO Medium (Motility Indole Ornithine Medium) M378
    MIO Medium (Motility Indole Ornithine Medium) M378 Motility Indole Ornithine Medium (MIO Medium) is used for the identification of Enterobacteriaceae on the basis of motility, indole production and ornithine decarboxylase activity. Composition** Ingredients Gms / Litre Casein enzymic hydrolysate 10.000 Peptic digest of animal tissue 10.000 Yeast extract 3.000 L-Ornithine hydrochloride 5.000 Dextrose 1.000 Bromocresol purple 0.020 Agar 2.000 Final pH ( at 25°C) 6.5±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 31.02 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely. Dispense in test tubes in 5 ml amounts. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool the tubes in an upright position. Principle And Interpretation Motility, indole production and ornithine decarboxylation are routine biochemical tests employed during identification of Enterobacteriaceae . Motility can be demonstrated microscopically (hanging drop) or macroscopically (tube method), where motility is observed as a diffused zone of growth flaring out from the line of inoculation. Indole test is carried out to determine the ability of an organism to split indole from tryptophan by the tryptophanase enzyme. On reaction with Kovacs reagent, indole combines with the colour in the alcohol layer, which is visualized as a red ring (in the alcohol layer) (1). If the test organisms possess the specific decarboxylase enzyme, then ornithine is decarboxylated to putrescine, an amine, resulting in a subsequent rise in the pH of the medium towards alkalinity. This causes the pH indicator bromocresol purple to change from purple to yellow colour.
    [Show full text]
  • Technical Report the Vitek Analyser for Routine Bacterial Identification And
    316 J Clin Pathol 1998;51:316–323 Technical report J Clin Pathol: first published as 10.1136/jcp.51.4.316 on 1 April 1998. Downloaded from The Vitek analyser for routine bacterial identification and susceptibility testing: protocols, problems, and pitfalls N Shetty, G Hill, G L Ridgway Abstract covered, maintenance and quality control Automated and semiautomated technol- costs, and the presence of a versatile software ogy in microbiology has seen great ad- package. This report describes our experiences vances in recent years. The choice of with the Vitek system (bioMerieux, UK) in the automated equipment for the identifica- one year since its inception into a busy micro- tion and susceptibility testing of bacteria biology diagnostic laboratory in the United in a routine diagnostic laboratory depends Kingdom. It is worth noting that the choice on speed, accuracy, ease of use, and cost and range of antibiotics on susceptibility factors. The Vitek analyser (bioMerieux, testing cards were custom made for the UK) was installed in a busy diagnostic University College London Hospitals teaching hospital laboratory in London. (UCLH). This report describes one year’s experience. Changes to work practice as a result of incorporating the equipment into Identification and susceptibility testing the laboratory, and the advantages and on the Vitek system disadvantages of automation in key areas Identification of microorganisms is accom- are described in detail, together with pos- plished by biochemical methods. A turbido- sible solutions to problems. The Vitek metrically controlled suspension of pure colo- analyser was found to be valuable for the nies in saline is inoculated into identification http://jcp.bmj.com/ speed and accuracy with which results cards.
    [Show full text]
  • Figure 1: Etest Gradient Configuration When an Etest Gradient Strip Is
    Inoculum preparation Table 1. Recommended media, inoculum and To obtain reproducible MICs from a gradient based Use the inoculum guide in TABLE 1. Emulsify several incubation1). system, the stability of the gradient must be maintai- well-isolated colonies from an overnight agar plate in lêÖ~åáëã= ^Ö~ê= fåçÅìäìã fåÅìÄ~íáçå ned throughout the critical period when the position a suitable suspension medium to achieve the specifi ed Öêçìé ãÉÇá~ of the growth/inhibition edge for a particular bac- inoculum turbidity by comparing to a McFarland pìëéÉåëáçå qìêÄáÇáíó= qÉãéÉê~íìêÉ= ^íãçëéÜÉêÉ qáãÉ= Antimicrobial Susceptibility Testing terium/antibiotic combination is determined. Due turbidity standard. For fastidious organisms such as EjÅc~êä~åÇF Eœ=O=ø`F EÜçìêëF For In Vitro Diagnostic Use to the stability and precision of the Etest predefi ned pneumococci, streptococci, gonococci, anaerobes and gradient, MIC values have been shown to be repro- Haemophilus spp., use the suspension prepared in INTENDED USE ducible and equivalent to those of the CLSI reference broth within 15 minutes. ^ÉêçÄÉë jìÉääÉê= MKURB=k~`ä MKR================== PR=ø` ~ãÄáÉåí NSJOM Etest is a quantitative technique for determining dilution procedures. eáåíçå EN=áÑ=ãìÅçáÇF the antimicrobial susceptibility of Gram negative Inoculation and Gram positive aerobic bacteria such as En- REAGENTS Soak a sterile, non-toxic swab in the inoculum terobacteriaceae, Pseudomonas, Staphylococcus and Etest is supplied in a package of 100 or 30 (some suspension and remove excess fl uid by pressing it lop^L=lopb jìÉääÉê= MKURB=k~`ä MKR PR=ø` ~ãÄáÉåí OQ=lop^==== Enterococcus species and fastidious bacteria, such as reagents) test strips of one antimicrobial agent.
    [Show full text]
  • 05686 DMACA (Indol Detection Disks)
    05686 DMACA (Indol Detection Disks) The DMACA Indole discs are used for Indole test to determine the ability of an organism to split tryptophan into indole and α-aminopropionic acid. The presence of indole can be detected by the addition of DMACA which results in a bluish-purple complex. With this method it is possible to differentiate Escherichia coli from Klebsiella. Composition: (1 package contains 50 disks) The discs contain p-Dimethylaminocinnamaldehyde (DMACA). Directions: Place the disc on suspected colony from e.g. UTI ChromoSelect Agar, modified (16636) or Christensen’s Urea Agar (27048) plate on filter paper. Observe for appearance of blue-purple color within 10-30 seconds. Quality control: Test Organisms (ATCC) DMACA Escherichia coli (25922) + Pseudomonas aeruginosa (27853) - Klebsiella pneumoniae (13883) - 1. Staphylococcus aureus 2. Escherichia coli Page 1 of 2 References: 1. R. Vracko, J.C. Sherris, Indole-spot test in bacteriology., Am. J. Clin. Pathol., 39, 429 (1963) 2. V.L. Sutter, W.T. Carter, Evaluation of media and reagents for indole-spot test in anaerobic bacteriology., Am. J. Clin. Pathol., 58, 335 (1972) 3. G.D. Fay, A.L. Barry, Methods for detecting indole production by gram-negative nonsporeforming anaerobes., Appl. Micro. 27, 562 (1974) 4. D.F. Welch, P.A. Ahlin, J.M. Matsen, Differentiation of Haemophilus spp. in respiratory isolate cultures by an indole spot test., J. Clin. Micro. 15, 216 (1982) 5. H.D. Isenberg, Ed., Clinical microbiology procedures handbook, Vol 1., Washington, DC, ASM (1992) 6. B.A. Forbes, D.F. Sahm, A.S. Weissfeld, Bailey and Scott's diagnostic microbiology., 10th ed., St Louis, Mosby (1998) 7.
    [Show full text]
  • Laboratory Exercises in Microbiology: Discovering the Unseen World Through Hands-On Investigation
    City University of New York (CUNY) CUNY Academic Works Open Educational Resources Queensborough Community College 2016 Laboratory Exercises in Microbiology: Discovering the Unseen World Through Hands-On Investigation Joan Petersen CUNY Queensborough Community College Susan McLaughlin CUNY Queensborough Community College How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/qb_oers/16 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] Laboratory Exercises in Microbiology: Discovering the Unseen World through Hands-On Investigation By Dr. Susan McLaughlin & Dr. Joan Petersen Queensborough Community College Laboratory Exercises in Microbiology: Discovering the Unseen World through Hands-On Investigation Table of Contents Preface………………………………………………………………………………………i Acknowledgments…………………………………………………………………………..ii Microbiology Lab Safety Instructions…………………………………………………...... iii Lab 1. Introduction to Microscopy and Diversity of Cell Types……………………......... 1 Lab 2. Introduction to Aseptic Techniques and Growth Media………………………...... 19 Lab 3. Preparation of Bacterial Smears and Introduction to Staining…………………...... 37 Lab 4. Acid fast and Endospore Staining……………………………………………......... 49 Lab 5. Metabolic Activities of Bacteria…………………………………………….…....... 59 Lab 6. Dichotomous Keys……………………………………………………………......... 77 Lab 7. The Effect of Physical Factors on Microbial Growth……………………………... 85 Lab 8. Chemical Control of Microbial Growth—Disinfectants and Antibiotics…………. 99 Lab 9. The Microbiology of Milk and Food………………………………………………. 111 Lab 10. The Eukaryotes………………………………………………………………........ 123 Lab 11. Clinical Microbiology I; Anaerobic pathogens; Vectors of Infectious Disease….. 141 Lab 12. Clinical Microbiology II—Immunology and the Biolog System………………… 153 Lab 13. Putting it all Together: Case Studies in Microbiology…………………………… 163 Appendix I.
    [Show full text]
  • Francisella Tularensis 6/06 Tularemia Is a Commonly Acquired Laboratory Colony Morphology Infection; All Work on Suspect F
    Francisella tularensis 6/06 Tularemia is a commonly acquired laboratory Colony Morphology infection; all work on suspect F. tularensis cultures .Aerobic, fastidious, requires cysteine for growth should be performed at minimum under BSL2 .Grows poorly on Blood Agar (BA) conditions with BSL3 practices. .Chocolate Agar (CA): tiny, grey-white, opaque A colonies, 1-2 mm ≥48hr B .Cysteine Heart Agar (CHA): greenish-blue colonies, 2-4 mm ≥48h .Colonies are butyrous and smooth Gram Stain .Tiny, 0.2–0.7 μm pleomorphic, poorly stained gram-negative coccobacilli .Mostly single cells Growth on BA (A) 48 h, (B) 72 h Biochemical/Test Reactions .Oxidase: Negative A B .Catalase: Weak positive .Urease: Negative Additional Information .Can be misidentified as: Haemophilus influenzae, Actinobacillus spp. by automated ID systems .Infective Dose: 10 colony forming units Biosafety Level 3 agent (once Francisella tularensis is . Growth on CA (A) 48 h, (B) 72 h suspected, work should only be done in a certified Class II Biosafety Cabinet) .Transmission: Inhalation, insect bite, contact with tissues or bodily fluids of infected animals .Contagious: No Acceptable Specimen Types .Tissue biopsy .Whole blood: 5-10 ml blood in EDTA, and/or Inoculated blood culture bottle Swab of lesion in transport media . Gram stain Sentinel Laboratory Rule-Out of Francisella tularensis Oxidase Little to no growth on BA >48 h Small, grey-white opaque colonies on CA after ≥48 h at 35/37ºC Positive Weak Negative Positive Catalase Tiny, pleomorphic, faintly stained, gram-negative coccobacilli (red, round, and random) Perform all additional work in a certified Class II Positive Biosafety Cabinet Weak Negative Positive *Oxidase: Negative Urease *Catalase: Weak positive *Urease: Negative *Oxidase, Catalase, and Urease: Appearances of test results are not agent-specific.
    [Show full text]
  • Biofire Blood Culture Identification System (BCID) Fact Sheet
    BioFire Blood Culture Identification System (BCID) Fact Sheet What is BioFire BioFire BCID is a multiplex polymerase chain reaction (PCR) test designed to BCID? identify 24 different microorganism targets and three antibiotic resistance genes from positive blood culture bottles. What is the purpose The purpose of BCID is to rapidly identify common microorganisms and of BCID? antibiotic resistance genes from positive blood cultures so that antimicrobial therapy can be quickly optimized by the physician and the antibiotic stewardship pharmacist. It is anticipated that this will result in improved patient outcomes, decreased length of stay, improved antibiotic stewardship, and decreased costs. When will BCID be BCID is performed on all initially positive blood cultures after the gram stain is routinely performed and reported. performed? When will BCID not For blood cultures on the same patient that subsequently become positive with be routinely a microorganism showing the same morphology as the initial positive blood performed? culture, BCID will not be performed. BCID will not be performed on positive blood cultures with gram positive bacilli unless Listeria is suspected. BCID will not be performed on blood culture bottles > 8 hours after becoming positive. BCID will not be performed between 10PM-7AM on weekdays and 2PM-7AM on weekends. BCID will not be performed for clinics that have specifically opted out of testing. How soon will BCID After the blood culture becomes positive and the gram stain is performed and results be available? reported, the bottle will be sent to the core Microbiology lab by routine courier. BCID testing will then be performed. It is anticipated that total turnaround time will generally be 2-3 hours after the gram stain is reported.
    [Show full text]
  • Asymptomatic Bacteriuria Amongst the Inhabitants of Okigwe, Imo State Nigeria
    Nigerian Journal of Microbiology, Vol. 22(1): 16 30 – 1633 2008 Asymptomatic Bacteriuria Amongst the Inhabitants of Okigwe, Imo State Nigeria *Ugbogu, O.C and Enya, V. N Department of Microbiology, Abia State University, Uturu, Nigeria. Abstract The prevalence of asymptomatic bacteriuria amongst the inhabitants of Okigwe was investigated using culture techniques. The predominant bacteria isolated were Escherichia coli , Staphylococcus aureus , Klebsiella species, Pseudomonas aeruginosa and Proteus species. Out of the 120 urine samples examined 20.8% had asymptomatic bacteriuria. The percentage prevalence was 17.7% and 22.5% for males and females examined respectively. Escherichia coli was the most prevalent occurring in 18.2% of the samples while Klebsiella species and Proteus species that both occurred in 5% of the positive samples were the least. Traders were more affected than students and civil servants. There is need to encourage people to screen for asymptomatic bacteriuria in other to avert the consequences of the subsequent complications. Keywords: bacteriuria, occupation, prevalence, symptom. *Corresponding author; E-mail; [email protected] phone 07084159395 Introduction Materials and methods Normally urine and the urinary tract Population studied : above the entrance to the bladder are essentially The population for this study was a free of microorganisms (Nester et al ., 2004). randomly selected group of 120 aparently Bacteriuria is a condition in which bacteria are healthy individuals that were either students, present in urine. Asymptomatic bacteriuria is traders or civil servants in Okigwe. The study defined as significant bacteriuria when growth of population were of various age groups ranging ≥ 10 5 cfu/ml of freshly voided urine (Umeh et from 16 to 45 years.
    [Show full text]
  • Time-To-Positivity, Type of Culture Media and Oxidase Test Performed on Positive Blood Culture Vials to Predict Pseudomonas Aeru
    Original Nazaret Cobos-Trigueros1 Time-to-positivity, type of culture media and oxidase Yuliya Zboromyrska2 Laura Morata1 test performed on positive blood culture vials to predict Izaskun Alejo2 Cristina De La Calle1 Pseudomonas aeruginosa in patients with Gram-negative Andrea Vergara2 Celia Cardozo1 bacilli bacteraemia 1 Maria P. Arcas 1 1 Department of Infectious Diseases, Hospital Clínic, IDIBAPS, Barcelona University, Barcelona, Spain. Alex Soriano 2Department of Clinical Microbiology, Hospital Clínic, Barcelona University, Barcelona, Spain. Francesc Marco2 Josep Mensa1 Manel Almela2 Jose A. Martinez1 ABSTRACT Tiempo de positividad, tipo de medio de cultivo y prueba de oxidasa realizada en Introduction. The aim of this study was to determine the viales de hemocultivo positivos para predecir usefulness of oxidase test and time-to-positivity (TTP) in aer- Pseudomonas aeruginosa en pacientes con obic and anaerobic blood culture vials to detect the presence bacteriemia por bacilos gramnegativos of Pseudomonas aeruginosa in patients with Gram-negative bacilli (GNB) bacteraemia. RESUMEN Material and methods. TTP was recorded for each aer- obic and anaerobic blood culture vial of monomicrobial bac- Introducción. El objetivo del estudio fue determinar la utili- teraemia due to GNB. Oxidase test was performed in a pellet dad de la prueba de oxidasa y del tiempo de positividad del hemo- of the centrifuged content of the positive blood culture. An cultivo (TPH) para detectar la presencia de Pseudomonas aerugino- algorithm was developed in order to perform the oxidase test sa en pacientes con bacteriemia por bacilos gramnegativos (BGN). efficiently taking into account TTP and type of vial. Material y métodos. Se registró el TPH de cada vial ae- Results.
    [Show full text]